Purdue Pharma is privately held. (AP photo by Douglas Healey)
The deposition "is believed to be the only time a member of the Sackler family has been questioned under oath about the marketing of OxyContin and the addictive properties," Stat's David Armstrong and Andrew Joseph report. "Other records include marketing strategies and internal emails about them; documents concerning internal analyses of clinical trials; settlement communications from an earlier criminal case regarding the marketing of OxyContin; and information regarding how sales representatives marketed the drug."
Conway told the Louisville Courier Journal Friday, “Kentucky got many times over what any state has gotten from Purdue Pharma. After eight and a half years, I thought it was best to get what we could. I hope it all comes out, (that) all of the documents eventually get released, and sooner rather than later.”
Purdue has 30 days to appeal, and indicated that it would, either to the state Supreme Court or through a rehearing by the appeals court. Either could refuse further action.
Stat Editor Rick Berke said, “More than two years after we filed this suit, the scourge of opioid addiction has grown worse, and the questions have grown about Purdue’s practices in marketing OxyContin. It is vital that that we all learn as much as possible about the culpability of Purdue, and the consequences of the company’s decisions on the health of Americans.”